ImageneBio, Inc. (IMA)
Nasdaq · Healthcare · Biotechnology
$4.70+1.73%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $53.5M
- 52-week range
- $3.94 – $9.10
- 52-week change
- −44.84%
- EPS (trailing)
- −$4.09
Fiscal year to Dec 2025
- Revenue
- $800K (−77.14%)
- Net income
- −$45.3M
- Operating margin
- −6056.4%
- Diluted EPS
- −$9.64
From the company’s annual report on SEC EDGAR.
About ImageneBio, Inc.
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.
Headquarters: San Diego, United States · 18 employees · inmagenebio.com